Belgian outfit Cardio3 Biosciences attracted $5.5 million in new regional government funding. The nondilutive financing will help refinance some debt and also fuel U.S. commercialization plans for C-Cathez, its intramyocardial injection catheter, and its C-Cure stem cell treatment designed to treat heart failure and related ailments. Cardio3 bills the C-Cathez device as a standout that's designed to maximize retention of stem cell treatments in the heart once they're delivered. Cardio3's new funding comes from the Walloon region, and Walloon government minister Jean-Marc Nollet said in a statement that the investment is crucial to keeping up regional leadership in the development of cellular therapies. Item